Optimization and Validation of a Virtual Reality Orientation and Mobility Test for Inherited Retinal Degenerations.
Journal
Translational vision science & technology
ISSN: 2164-2591
Titre abrégé: Transl Vis Sci Technol
Pays: United States
ID NLM: 101595919
Informations de publication
Date de publication:
03 01 2023
03 01 2023
Historique:
entrez:
30
1
2023
pubmed:
31
1
2023
medline:
2
2
2023
Statut:
ppublish
Résumé
To optimize a virtual reality (VR) orientation and mobility (O&M) test of functional vision in patients with inherited retinal degenerations (IRDs). We developed an O&M test using commercially available VR hardware and custom-generated software. Normally sighted subjects (n = 20, ages = 14-67 years) and patients with IRDs (n = 29, ages = 15-63 years) participated. Individuals followed a dim red arrow path to a "course exit," while trying to identify nine obstacles adjacent to, or directly in their path. Dark-adapted subjects completed 35 randomly selected VR courses at increasing luminances, twice per luminance step, binocularly, and uni-ocularly. Performance was graded automatically by the software. Patients with IRD completed a modified Visual Function Questionnaire (VFQ). Normally sighted subjects identified approximately 50% of the obstacles at the dimmest course luminance. Except for two patients with IRD with poor vision, all patients were able to complete the test, although they required brighter (by >2 log units) luminances to identify 50% of the obstacles. In a single-luminance screening test in which normal subjects detected at least eight of nine objects, most patients with IRD underperformed; their performance related to disease severity, as measured by visual acuity, kinetic visual field extent, and VFQ scores. Test-retest differences in object detection were similar to the differences between the two eyes (±2 SD = ±2 objects). This VR-O&M test was able to distinguish subjects with IRDs from normal subjects reliably and reproducibly. This easily implemented, flexible, and objectively scored VR-O&M test promises to become a useful tool to assess the impact that IRDs and their treatments have on functional vision.
Identifiants
pubmed: 36716040
pii: 2785319
doi: 10.1167/tvst.12.1.28
pmc: PMC9896841
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
28Références
Clin Ophthalmol. 2021 Mar 02;15:939-952
pubmed: 33688162
Hum Factors. 1978 Jun;20(3):273-86
pubmed: 567170
Am J Ophthalmol. 2019 Mar;199:58-70
pubmed: 30268864
Clin Exp Ophthalmol. 2018 Apr;46(3):247-259
pubmed: 28697537
Clin Exp Optom. 2020 Jul;103(4):434-448
pubmed: 31838758
Hear Res. 2014 Apr;310:60-8
pubmed: 24524865
Am J Ophthalmol. 2021 Oct;230:12-47
pubmed: 34000280
Optom Vis Sci. 2016 Sep;93(9):1127-36
pubmed: 27254810
J Vis. 2016 Dec 1;16(15):5
pubmed: 27919101
Invest Ophthalmol Vis Sci. 2017 May 1;58(5):2609-2622
pubmed: 28510626
Semin Pediatr Neurol. 2019 Oct;31:30-40
pubmed: 31548022
J Glaucoma. 2020 Feb;29(2):86-91
pubmed: 31790067
Am J Optom Physiol Opt. 1982 May;59(5):413-26
pubmed: 7102800
Nat Med. 2022 May;28(5):1014-1021
pubmed: 35379979
Clin Exp Optom. 2016 May;99(3):227-32
pubmed: 26804484
Am J Occup Ther. 2015 Jan-Feb;69(1):6901290010p1-8
pubmed: 25553750
ACM Trans Appl Percept. 2007 Jan;4(1):8
pubmed: 18167511
J Neural Eng. 2007 Mar;4(1):S102-7
pubmed: 17325408
N Engl J Med. 2008 May 22;358(21):2231-9
pubmed: 18441371